A role for everolimus in post-transplant encapsulating peritoneal sclerosis: first case report.

Rahul Sud, Lorraine Garry, Stephen Timothy Spicer, Richard D M Allen, Josette M Eris, Kate Wyburn, Deborah Verran, Caroline Louise Cooper, Steve Chadban

Journal: Nephrology (Carlton, Vic.) 2014;19 Suppl 1():27-30

PMID: 24460661

Abstract

Encapsulating peritoneal sclerosis (EPS) is a rare complication of peritoneal dialysis (PD) that carries a high morbidity and mortality. The 'two hit theory' suggests that long term deterioration of the peritoneum combined with intraperitoneal inflammation is needed in the pathogenesis of EPS. For unclear reasons, post transplantation EPS is being increasingly reported in patients previously on PD. To date, there is no proven effective therapy with an absence of randomised controlled trials. Individual case reports and small case series have reported on the use of tamoxifen and corticosteroids for medical management of EPS. The use of everolimus has been reported in a single case, and never in the setting of renal transplantation. Here, we present the first case of post-transplant encapsulating peritoneal sclerosis treated successfully with a combination of everolimus, tamoxifen, low dose corticosteroid and surgery.

© 2014 Asian Pacific Society of Nephrology.

Address: Renal Unit, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.